Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-001386-37 | EudraCT Number |
Not provided
Not provided
Not provided
Based on interim analysis for futility and given an enrolment rate almost nil
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The clinical study aims at assessing whether early administration of Tocilizumab compared to late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation. The clinical study includes patients with recent-onset COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical ventilation procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Arm | Experimental | Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours |
|
| Control Arm | Other | Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tocilizumab | Drug | In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation | Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation documented by the finding of a PaO2 / FiO2 ratio <150mm / Hg confirmed by a second arterial blood gas (ABG) measurement within four hours | two weeks from participants' allocation to study arm |
| Measure | Description | Time Frame |
|---|---|---|
| Death from any cause | Death | Two weeks from participants' allocation to study arm |
| Tocilizumab toxicity | Adverse events (AE) classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carlo Salvarani, M.D. | Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia | Study Director |
| Massimo Costantini, Ph.D. | Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ospedale di Guastalla | Guastalla | RE | Italy | |||
| Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33080005 | Derived | Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turra C, Ballerini PF, Sciascia R, Zammarchi L, Para O, Scotton PG, Inojosa WO, Ravagnani V, Salerno ND, Sainaghi PP, Brignone A, Codeluppi M, Teopompi E, Milesi M, Bertomoro P, Claudio N, Salio M, Falcone M, Cenderello G, Donghi L, Del Bono V, Colombelli PL, Angheben A, Passaro A, Secondo G, Pascale R, Piazza I, Facciolongo N, Costantini M; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Two weeks from participants' allocation to study arm |
| Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment | Levels of ferritin, lactate dehydrogenase and D-dimer and their correlation with the effectiveness of the treatment | Two weeks from participants' allocation to study arm |
| Evaluate the progress of the PaO2 / FiO2 ratio | Changes from baseline of the PaO2 / FiO2 ratio | Two weeks from participants' allocation to study arm |
| Evaluate the trend over time of the lymphocyte count | Changes from baseline of the lymphocyte count | Two weeks from participants' allocation to study arm |
| Reggio Emilia |
| RE |
| 42122 |
| Italy |
| Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo | Alessandria | Italy |
| Policlinico Sant'Orsola Malpighi | Bologna | Italy |
| ASST Cremona | Cremona | Italy |
| Azienda Ospedaliera S. Croce e Carle | Cuneo | Italy |
| Azienda Ospedaliero Universitaria Ferrara | Ferrara | Italy |
| Azienda Ospedaliero Universitaria Careggi | Florence | Italy |
| Ospedale Evangelico Internazionale di Genova | Genova | Italy |
| Azienda Sociosanitaria ASL 1 ,Imperia | Imperia | Italy |
| Azienda Sociosanitaria ASL 5 La Spezia | La Spezia | Italy |
| ASST Mantova - Ospedale Carlo Poma | Mantua | Italy |
| IRCCS Istituto Auxologico Italiano Milano | Milan | Italy |
| Azienda Ospedaliero-Universitaria "Maggiore della Carità " di Novara | Novara | Italy |
| Ospedali Riuniti Padova Sud - ULSS 6 Euganea | Padova | Italy |
| Azienda Ospedaliero-Universitaria Parma | Parma | Italy |
| Azienda Unità Sanitaria Locale di Piacenza | Piacenza | Italy |
| Azienda Ospedaliera Universitaria Pisana | Pisa | Italy |
| AO Ordine Mauriziano di Torino | Torino | Italy |
| ASST Bergamo Ovest -Treviglio | Treviglio | Italy |
| AULSS 2 Marca Trevigiana | Treviso | Italy |
| AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto | Treviso | Italy |
| AULSS 3 Serenissima Ospedale "Dell'Angelo" | Venezia | Italy |
| Azienda Ospedaliera Universitaria Integrata di Verona | Verona | Italy |
| IRCCS Sacro Cuore Don Calabria | Verona | Italy |
| ID | Term |
|---|---|
| C502936 | tocilizumab |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided